Tipepidine: Difference between revisions
No edit summary |
No edit summary |
||
Line 2: | Line 2: | ||
| verifiedrevid = 447810095 | | verifiedrevid = 447810095 | ||
| IUPAC_name = 3-(di-2-thienylmethylene)-1-methylpiperidine | | IUPAC_name = 3-(di-2-thienylmethylene)-1-methylpiperidine | ||
| image = Tipepidine. | | image = Tipepidine.png | ||
<!--Clinical data--> | <!--Clinical data--> | ||
Line 50: | Line 50: | ||
| StdInChIKey = JWIXXNLOKOAAQT-UHFFFAOYSA-N | | StdInChIKey = JWIXXNLOKOAAQT-UHFFFAOYSA-N | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Tipepidine''' ([[International Nonproprietary Name|INN]]) (brand names '''Asverin''', '''Antupex''', '''Asvelik''', '''Asvex''', '''Bitiodin''', '''Cofdenin A''', '''Hustel''', '''Nodal''', '''Sotal'''), also known as '''tipepidine hibenzate''' ([[Japanese Accepted Name|JAN]]), is a [[Organic compound#Synthetic compounds|synthetic]], non-[[opioid]] [[antitussive]] and [[expectorant]] of the [[thiambutene]] class.<ref name="GanellinTriggle1996">{{cite book|author1=C.R. Ganellin|author2=David J. Triggle|title=Dictionary of Pharmacological Agents|url=http://books.google.com/books?id=A0THacd46ZsC&pg=PA1988|date=21 November 1996|publisher=CRC Press|isbn=978-0-412-46630-4|pages=1988–}}</ref><ref>{{cite book|title=Index Nominum 2000: International Drug Directory|url=http://books.google.com/books?id=5GpcTQD_L2oC&pg=PA1649|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=1649–}}</ref> It acts as an [[channel blocker|inhibitor]] of [[G protein-coupled inwardly-rectifying potassium channel]]s (GIRKs).<ref name="KawauraOgata2009">{{cite journal|last1=Kawaura|first1=Kazuaki|last2=Ogata|first2=Yukino|last3=Inoue|first3=Masako|last4=Honda|first4=Sokichi|last5=Soeda|first5=Fumio|last6=Shirasaki|first6=Tetsuya|last7=Takahama|first7=Kazuo|title=The centrally acting non-narcotic antitussive tipepidine produces antidepressant-like effect in the forced swimming test in rats|journal=Behavioural Brain Research|volume=205|issue=1|year=2009|pages=315–318|issn=01664328|doi=10.1016/j.bbr.2009.07.004}}</ref> The drug was discovered in the 1950s,<ref>ES Patent 272195</ref> and was developed in [[Japan]] in 1959.<ref name="ImaiIshii2011">{{cite journal|last1=Imai|first1=Yuki|last2=Ishii|first2=Wakako|last3=Endo|first3=Ayumi|last4=Arakawa|first4=Chikako|last5=Kohira|first5=Ryutaro|last6=Fujita|first6=Yukihiko|last7=Fuchigami|first7=Tatsuo|last8=Mugishima|first8=Hideo|title=Tipepidine hibenzate intoxication|journal=Pediatrics International|volume=53|issue=5|year=2011|pages=779–781|issn=13288067|doi=10.1111/j.1442-200X.2010.03297.x}}</ref> It is used as the [[hibenzate]] and [[citrate]] salts.<ref name="GanellinTriggle1996" /><ref name="ImaiIshii2011" /> | '''Tipepidine''' ([[International Nonproprietary Name|INN]]) (brand names '''Asverin''', '''Antupex''', '''Asvelik''', '''Asvex''', '''Bitiodin''', '''Cofdenin A''', '''Hustel''', '''Nodal''', '''Sotal'''), also known as '''tipepidine hibenzate''' ([[Japanese Accepted Name|JAN]]), is a [[Organic compound#Synthetic compounds|synthetic]], non-[[opioid]] [[antitussive]] and [[expectorant]] of the [[thiambutene]] class.<ref name="GanellinTriggle1996">{{cite book|author1=C.R. Ganellin|author2=David J. Triggle|title=Dictionary of Pharmacological Agents|url=http://books.google.com/books?id=A0THacd46ZsC&pg=PA1988|date=21 November 1996|publisher=CRC Press|isbn=978-0-412-46630-4|pages=1988–}}</ref><ref>{{cite book|title=Index Nominum 2000: International Drug Directory|url=http://books.google.com/books?id=5GpcTQD_L2oC&pg=PA1649|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=1649–}}</ref> It acts as an [[channel blocker|inhibitor]] of [[G protein-coupled inwardly-rectifying potassium channel]]s (GIRKs).<ref name="KawauraOgata2009">{{cite journal|last1=Kawaura|first1=Kazuaki|last2=Ogata|first2=Yukino|last3=Inoue|first3=Masako|last4=Honda|first4=Sokichi|last5=Soeda|first5=Fumio|last6=Shirasaki|first6=Tetsuya|last7=Takahama|first7=Kazuo|title=The centrally acting non-narcotic antitussive tipepidine produces antidepressant-like effect in the forced swimming test in rats|journal=Behavioural Brain Research|volume=205|issue=1|year=2009|pages=315–318|issn=01664328|doi=10.1016/j.bbr.2009.07.004}}</ref> The drug was discovered in the 1950s,<ref>ES Patent 272195</ref> and was developed in [[Japan]] in 1959.<ref name="ImaiIshii2011">{{cite journal|last1=Imai|first1=Yuki|last2=Ishii|first2=Wakako|last3=Endo|first3=Ayumi|last4=Arakawa|first4=Chikako|last5=Kohira|first5=Ryutaro|last6=Fujita|first6=Yukihiko|last7=Fuchigami|first7=Tatsuo|last8=Mugishima|first8=Hideo|title=Tipepidine hibenzate intoxication|journal=Pediatrics International|volume=53|issue=5|year=2011|pages=779–781|issn=13288067|doi=10.1111/j.1442-200X.2010.03297.x}}</ref> It is used as the [[hibenzate]] and [[citrate]] salts.<ref name="GanellinTriggle1996" /><ref name="ImaiIshii2011" /> | ||
The usual dose is 20 mg every 4–6 hours.{{Citation needed|date=February 2015}} Possible [[side effect]]s of tipepidine, especially in [[overdose]], may include [[drowsiness]], [[vertigo]], [[delirium]], [[disorientation]], [[loss of consciousness]], and [[confusion]].<ref name="ImaiIshii2011" /> | The usual dose is 20 mg every 4–6 hours.{{Citation needed|date=February 2015}} Possible [[side effect]]s of tipepidine, especially in [[overdose]], may include [[drowsiness]], [[vertigo]], [[delirium]], [[disorientation]], [[loss of consciousness]], and [[confusion]].<ref name="ImaiIshii2011" /> | ||
Line 65: | Line 68: | ||
{{Cough and cold preparations}} | {{Cough and cold preparations}} | ||
[[Category:Antitussives]] | [[Category:Antitussives]] | ||
[[Category: | [[Category:Drug]] | ||
[[Category:Expectorants]] | [[Category:Expectorants]] | ||
[[Category:Thiophenes]] | [[Category:Thiophenes]] | ||
[[Category:Piperidines]] | [[Category:Piperidines]] | ||
Latest revision as of 16:00, 9 April 2015
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C15H17NS2 |
Molar mass | 275.434 g/mol |
3D model (JSmol) | |
| |
| |
(verify) |
WikiDoc Resources for Tipepidine |
Articles |
---|
Most recent articles on Tipepidine |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Tipepidine at Clinical Trials.gov Clinical Trials on Tipepidine at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Tipepidine
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Tipepidine Discussion groups on Tipepidine Patient Handouts on Tipepidine Directions to Hospitals Treating Tipepidine Risk calculators and risk factors for Tipepidine
|
Healthcare Provider Resources |
Causes & Risk Factors for Tipepidine |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Tipepidine (INN) (brand names Asverin, Antupex, Asvelik, Asvex, Bitiodin, Cofdenin A, Hustel, Nodal, Sotal), also known as tipepidine hibenzate (JAN), is a synthetic, non-opioid antitussive and expectorant of the thiambutene class.[1][2] It acts as an inhibitor of G protein-coupled inwardly-rectifying potassium channels (GIRKs).[3] The drug was discovered in the 1950s,[4] and was developed in Japan in 1959.[5] It is used as the hibenzate and citrate salts.[1][5] The usual dose is 20 mg every 4–6 hours.[citation needed] Possible side effects of tipepidine, especially in overdose, may include drowsiness, vertigo, delirium, disorientation, loss of consciousness, and confusion.[5]
Tipepidine has recently garnered interest as a potential psychiatric drug. It is being investigated in depression,[3][6][7] obsessive-compulsive disorder,[8] and attention-deficit hyperactivity disorder (ADHD).[9][10] Through inhibition of GIRK channels, tipepidine increases dopamine levels in the nucleus accumbens, but without increasing locomotor activity or producing methamphetamine-like behavioral sensitization, and this action appears to be at least partly responsible for its antidepressant-like effects in rodents.[11][12]
See also
References
- ↑ 1.0 1.1 C.R. Ganellin; David J. Triggle (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 1988–. ISBN 978-0-412-46630-4.
- ↑ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 1649–. ISBN 978-3-88763-075-1.
- ↑ 3.0 3.1 Kawaura, Kazuaki; Ogata, Yukino; Inoue, Masako; Honda, Sokichi; Soeda, Fumio; Shirasaki, Tetsuya; Takahama, Kazuo (2009). "The centrally acting non-narcotic antitussive tipepidine produces antidepressant-like effect in the forced swimming test in rats". Behavioural Brain Research. 205 (1): 315–318. doi:10.1016/j.bbr.2009.07.004. ISSN 0166-4328.
- ↑ ES Patent 272195
- ↑ 5.0 5.1 5.2 Imai, Yuki; Ishii, Wakako; Endo, Ayumi; Arakawa, Chikako; Kohira, Ryutaro; Fujita, Yukihiko; Fuchigami, Tatsuo; Mugishima, Hideo (2011). "Tipepidine hibenzate intoxication". Pediatrics International. 53 (5): 779–781. doi:10.1111/j.1442-200X.2010.03297.x. ISSN 1328-8067.
- ↑ KAWAURA, Kazuaki; HONDA, Sokichi; SOEDA, Fumio; SHIRASAKI, Tetsuya; TAKAHAMA, Kazuo (2010). "A Novel Antidepressant-like Action of Drugs Possessing GIRK Channel Blocking Action in Rats". YAKUGAKU ZASSHI. 130 (5): 699–705. doi:10.1248/yakushi.130.699. ISSN 0031-6903.
- ↑ Sasaki T, Hashimoto K, Tachibana M, Kurata T, Kimura H, Komatsu H, et al. (2014). "Tipepidine in adolescent patients with depression: a 4 week, open-label, preliminary study". Neuropsychiatr Dis Treat. 10: 719–22. doi:10.2147/NDT.S63075. PMC 4015794. PMID 24833905.
- ↑ Honda, Sokichi; Kawaura, Kazuaki; Soeda, Fumio; Shirasaki, Tetsuya; Takahama, Kazuo (2011). "The potent inhibitory effect of tipepidine on marble-burying behavior in mice". Behavioural Brain Research. 216 (1): 308–312. doi:10.1016/j.bbr.2010.08.010. ISSN 0166-4328.
- ↑ Sasaki T, Hashimoto K, Tachibana M, Kurata T, Okawada K, Ishikawa M, et al. (2014). "Tipepidine in children with attention deficit/hyperactivity disorder: a 4-week, open-label, preliminary study". Neuropsychiatr Dis Treat. 10: 147–51. doi:10.2147/NDT.S58480. PMC 3908907. PMID 24493927.
- ↑ Hashimoto, K.; Sasaki, T. (2014). "Old drug tipepidine as new hope for children with ADHD". Australian & New Zealand Journal of Psychiatry. 49 (2): 181–182. doi:10.1177/0004867414553952. ISSN 0004-8674.
- ↑ Hamasaki R, Shirasaki T, Soeda F, Takahama K (2013). "Tipepidine activates VTA dopamine neuron via inhibiting dopamine D₂ receptor-mediated inward rectifying K⁺ current". Neuroscience. 252: 24–34. doi:10.1016/j.neuroscience.2013.07.044. PMID 23896570.
- ↑ Hamao K, Kawaura K, Soeda F, Hamasaki R, Shirasaki T, Takahama K (2015). "Tipepidine increases dopamine level in the nucleus accumbens without methamphetamine-like behavioral sensitization". Behav. Brain Res. doi:10.1016/j.bbr.2015.02.012. PMID 25687844.
- Pages with script errors
- Template:drugs.com link with non-standard subpage
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without DrugBank identifier
- All articles with unsourced statements
- Articles with unsourced statements from February 2015
- Articles with invalid date parameter in template
- Antitussives
- Drug
- Expectorants
- Thiophenes
- Piperidines